Skip to main content

Knowledge

HKBU and Cornell University jointly develop a novel nano-carrier that increases the efficacy of Chinese medicine treatment for breast cancer 

11 May 2021

A research team led by Professor Bian Zhaoxiang (left) and Dr Kwan Hiu-yee (right) collaborates with Cornell University to develop a nano-carrier that increases treatment efficacy of gambogic acid for TNBC.
A research team led by Professor Bian Zhaoxiang (left) and Dr Kwan Hiu-yee (right) collaborates with Cornell University to develop a nano-carrier that increases treatment efficacy of gambogic acid for TNBC.

Professor Bian Zhaoxiang, Director and Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies of the Clinical Division of the School of Chinese Medicine (SCM) and Dr Kwan Hiu-yee, Assistant Professor of the Teaching and Research Division of SCM, in collaboration with Cornell University, have developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound gambogic acid (GA). 

 

The invention enhances the anti-cancer effect of GA and reduces its damage to off-target organs. The invention has the potential to become a more effective therapeutic option for TNBC.

 

“The application of nanotechnology in this study modernises the delivery of Chinese medicine, thereby enhancing its therapeutic efficacy. We believe that our nano-carriers have great clinical potential to treat TNBC and other types of cancer,” said Professor Bian.

 

The study was supported by the Vincent and Lily Woo Foundation, and the research findings have been published in the international medical journal Frontiers in Oncology. 

 

Please click here for more details.